FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED

Fisher & Paykel Healthcare Corporation Limited

Equities

FPH

NZFAPE0001S2

Medical Equipment, Supplies & Distribution

End-of-day quote New Zealand S.E. Other stock markets 09/07/2025			5-day change	1st Jan Change
36.82 ^NZD	-0.35%		-1.81%	-4.11%

29/05	Fisher & Paykel Healthcare Corporation Limited Provides Earnings Guidance for the Financial Year 2026	CI
28/05	Fisher & Paykel Healthcare's Fiscal 2025 Results Beat Expectations, Wilsons Advisory Says	MT

Fisher & Paykel Healthcare Corporation Limited Announces the Ordinary Unfranked Dividend for the Six Months Ended March 31, 2025, Payable on July 04, 2025

Published on 04/07/2025 at 18:05

Fisher & Paykel Healthcare Corporation Limited announced the ordinary unfranked dividend of NZD 0.28235294 per share for the six months ended March 31, 2025, payable on July 04, 2025. Record date is on June 24, 2025 with Ex date is on June 23, 2025.

Latest news about Fisher & Paykel Healthcare Corporation Limited

Fisher & Paykel Healthcare Corporation Limited Provides Earnings Guidance for the Financial Year 2026	29/05	CI
Fisher & Paykel Healthcare's Fiscal 2025 Results Beat Expectations, Wilsons Advisory Says	28/05	MT
Fisher & Paykel Healthcare Corporation Limited, 2025 Earnings Call, May 28, 2025	28/05
NZX Midday Sector Update: Consumer Durables Soar, Health Technology Falls	28/05	MT
Fisher & Paykel Healthcare Corporation Limited Reports Earnings Results for the Full Year Ended March 31, 2025	28/05	CI
Fisher & Paykel Healthcare Expects FY Operating Revenue To Be NZ$2.15 Bln To NZ$2.25 Bln	28/05	RE
ASX Preview: Australian Shares to Open Higher as Wall Street Rallies on US-EU Trade Truce; Fisher & Paykel Posts Upbeat Fiscal 2025 Results	28/05	MT
Fisher & Paykel Healthcare Posts Fiscal 2025 Underlying EPS of NZ$0.639, Operating Revenue of NZ$2.02 Billion	28/05	MT
New Zealand Shares Rise Helped by Health Tech Sector; Infratil Now Owns 49.75% Stake in CDC	21/05	MT
NZX Midday Sector Update: Health Technology Soars, Producer Manufacturing Struggles	21/05	MT
UBS Downgrades Fisher & Paykel Healthcare to Neutral From Buy; Price Target is NZ$39	20/05	MT
New Zealand Shares Rise Despite Decline in Asian Shares, Sanford Posts Higher H1 Earnings	15/05	MT
Tariffs on US Imports to Rise to Highest Level in Almost a Hundred Years; Jarden Research Says	04/04	MT
Australian Shares Fall as Tariffs Cause Global Selloff; Fisher & Paykel Expects Higher Costs in Fiscal Year 2026	03/04	MT
Fisher & Paykel Healthcare Says Does Not Anticipate Material Impact From US Tariffs On FY25 NPAT	03/04	RE
ASX Preview: Australian Shares to Open Higher as Global Markets Digest Sweeping Tariffs From US	03/04	MT
Fisher & Paykel Expects Higher Costs in Fiscal 2026 Due to New US Tariffs; Shares Fall 5%	03/04	MT
NZX Midday Sector Update: Health Technology Soars, Technology Services Tanks	02/04	MT
NZX Midday Sector Update: Health Technology Soars, Consumer Durables Tank	26/03	MT
New Zealand Shares Fall as Investors Track Wall Street Losses on Continued Trade Jitters	12/03	MT
Fisher & Paykel Healthcare Launches F&P Nova Nasal Mask for Obstructive Sleep Apnea in Australia, New Zealand	12/03	MT
Fisher & Paykel Healthcare Launches F+P Nova Nasal Mask In NZ And AU	12/03	RE
Fisher & Paykel Healthcare Launches F&P Nova Nasal Mask in New Zealand and Australia	12/03	CI
New Zealand Shares Flat, Asian Equities Track Wall Street Gains on Tariff Reprieve, China Stimulus Hopes	06/03	MT
Fisher & Paykel Healthcare Enters Construction Contract For Fifth NZ Building	06/03	RE

Chart Fisher & Paykel Healthcare Corporation Limited

Duration

Period

Chart Fisher & Paykel Healthcare Corporation Limited

FPH: Dynamic Chart

Company Profile

Fisher & Paykel Healthcare Corporation Limited designs, manufactures and markets products and systems for use in acute and chronic respiratory care, surgery, and the treatment of obstructive sleep apnea. The Company provides medical device products and systems for use in both hospital and homecare settings. Its hospital product group includes products used in invasive ventilation, noninvasive ventilation, nasal high flow therapy, anesthesia, and laparoscopic and open surgery. Its homecare product group includes devices and systems used to treat obstructive sleep apnea (OSA) and provide respiratory support in the home, which include its continuous positive airway pressure (CPAP) therapy masks as well as flow generators, interfaces, and data management technologies. The Companyâs products are sold in over 120 countries worldwide. It operates across Canada, the United States of America, Mexico, Costa Rica, the United Kingdom, Switzerland, India, and others.

Employees

7,412

Sector

Medical Equipment, Supplies & Distribution

Calendar

23/07 - Investor Meeting

More about the company